International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Olivera, Pablo A.; Zuily, Stephane; Kotze, Paulo G.; Regnault, Veronique; Al Awadhi, Sameer; Bossuyt, Peter; Gearry, Richard B.; Ghosh, Subrata; Kobayashi, Taku; Lacolley, Patrick; Louis, Edouard; Magro, Fernando; Ng, Siew C.; Papa, Alfredo; Raine, Tim; Teixeira, Fabio V.; Rubin, David T.; Danese, Silvio; Peyrin-Biroulet, Laurent

doi:10.1038/s41575-021-00492-8

Article (Scientific journals)

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Olivera, Pablo A.; Zuily, Stephane; Kotze, Paulo G. et al.

2021 • In Nature Reviews Gastroenterology and Hepatology, 18 (12), p. 857-873

Permalink
https://hdl.handle.net/2268/266127

DOI
10.1038/s41575-021-00492-8

PubMed
34453143

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

International consensus on the prevention of venous and arterial thrombotic events in patients with IBD_NatRevGastroenterolHepatol_PPE.pdf

Publisher postprint (8.85 MB)

Download

© 2021. The Author(s) - This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

prevention; venous and arterial thrombotic events; IBD

Abstract :

[en] Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as 'fully agree' or 'mostly agree' with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Olivera, Pablo A.

Zuily, Stephane

Kotze, Paulo G.

Regnault, Veronique

Al Awadhi, Sameer

Bossuyt, Peter

Gearry, Richard B.

Ghosh, Subrata

Kobayashi, Taku

Lacolley, Patrick

More authors (9 more)

Language :

English

Title :

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Publication date :

2021

Journal title :

Nature Reviews Gastroenterology and Hepatology

ISSN :

1759-5045

eISSN :

1759-5053

Publisher :

Nature Publishing Group, London, United Kingdom

Volume :

Issue :

Pages :

857-873

Additional URL :

https://doi.org/10.1038/s41575-021-00492-8

Commentary :

Available on ORBi :

since 15 December 2021

Statistics

Number of views

63 (3 by ULiège)

Number of downloads

47 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L. & Colombel, J.-F. Ulcerative colitis. Lancet 389, 1756–1770 (2017).
Roda, G. et al. Crohn’s disease. Nat. Rev. Dis. Prim. 6, 22 (2020).
van Sommeren, S. et al. Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways. Inflamm. Bowel Dis. 20, 987–994 (2014).
Argollo, M. et al. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol. Hepatol. 4, 643–654 (2019).
Papa, A. et al. Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. Inflamm. Bowel Dis. 21, 1204–1213 (2015).
Danese, S. et al. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am. J. Gastroenterol. 102, 174–186 (2007).
Lagrange, J., Lacolley, P., Wahl, D., Peyrin-Biroulet, L. & Regnault, V. Shedding light on hemostasis in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 19, 1088–1097.e6 (2021).
Bigeh, A., Sanchez, A., Maestas, C. & Gulati, M. Inflammatory bowel disease and the risk for cardiovascular disease: does all inflammation lead to heart disease? Trends Cardiovasc. Med. 30, 463–469 (2020).
Pai, J. K. et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 351, 2599–2610 (2004).
Tinsley, A. et al. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J. Crohns Colitis 7, e635–e640 (2013).
Lambin, T., Faye, A. S. & Colombel, J.-F. Inflammatory bowel disease therapy and venous thromboembolism. Curr. Treat. Options Gastroenterol. 18, 462–475 (2020).
Baker, A., Young, K., Potter, J. & Madan, I. A review of grading systems for evidence-based guidelines produced by medical specialties. Clin. Med. 10, 358–363 (2010).
Isene, R. et al. Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort. Scand. J. Gastroenterol. 49, 820–825 (2014).
Kappelman, M. D. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 60, 937–943 (2011).
Nguyen, G. C. & Sam, J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 103, 2272–2280 (2008).
Vegh, Z. et al. Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort. Scand. J. Gastroenterol. 50, 306–311 (2014).
Weng, M. T. et al. Incidence and risk factor analysis of thromboembolic events in East Asian patients with inflammatory bowel disease, a multinational collaborative study. Inflamm. Bowel Dis. 24, 1791–1800 (2018).
Yuhara, H. et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 37, 953–962 (2013).
Fumery, M. et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J. Crohns Colitis 8, 469–479 (2014).
Spencer, F. A. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med. 21, 722–727 (2006).
Kearon, C. et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J. Thromb. Haemost. 14, 1480–1483 (2016).
Iorio, A. et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor. Arch. Intern. Med. 170, 1710–1716 (2010).
Papa, A., Danese, S., Grillo, A., Gasbarrini, G. & Gasbarrini, A. Review article: inherited thrombophilia in inflammatory bowel disease. Am. J. Gastroenterol. 98, 1247–1251 (2003).
Kader, H. A. et al. Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 35, 629–635 (2002).
Liang, J. et al. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. J. Gastroenterol. 46, 1158–1166 (2011).
Zhong, M., Dong, X. W., Zheng, Q., Tong, J. L. & Ran, Z. H. Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis. Thromb. Res. 128, 403–409 (2011).
Bernstein, C. N., Sargent, M., Vos, H. L. & Rosendaal, F. R. Mutations in clotting factors and inflammatory bowel disease. Am. J. Gastroenterol. 102, 338–343 (2007).
Guédon, C. et al. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am. J. Gastroenterol. 96, 1448–1454 (2001).
Törüner, M. et al. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk. J. Gastroenterol. 15, 250–252 (2004).
Cappello, M. et al. Genetic predisposition to thrombophilia in inflammatory bowel disease. J. Clin. Gastroenterol. 45, e25–e29 (2011).
Spina, L. et al. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am. J. Gastroenterol. 100, 2036–2041 (2005).
Nguyen, G. C. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146, 835–848.e6 (2014).
Magro, F. et al. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 15, 1157–1163 (2003).
Koutroubakis, I. E. et al. Anti-cardiolipin and anti-β2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 43, 2507–2512 (1998).
Aichbichler, B. W. et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 44, 852–856 (1999).
Sipeki, N. et al. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease. World J. Gastroenterol. 21, 6952–6964 (2015).
Saibeni, S. et al. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig. Dis. Sci. 46, 637–643 (2001).
Koutroubakis, I. E. et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 95, 190–194 (2000).
Zezos, P. et al. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis. Hepatogastroenterology 54, 1417–1421 (2007).
Cakal, B. et al. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. Blood Coagul. Fibrinolysis 21, 118–121 (2010).
Goldhaber, S. Z. Risk factors for venous thromboembolism. J. Am. Coll. Cardiol. 56, 1–7 (2010).
Schünemann, H. J. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2, 3198–3225 (2018).
Spyropoulos, A. C., McGinn, T. & Khorana, A. A. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb. Haemost. 108, 1072–1076 (2012).
Gould, M. K. et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e227S–e277S (2012).
Barbar, S. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J. Thromb. Haemost. 8, 2450–2457 (2010).
Spyropoulos, A. C. et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140, 706–714 (2011).
Nendaz, M. et al. Multicentre validation of the Geneva risk score for hospitalised medical patients at risk of venous thromboembolism. Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE). Thromb. Haemost. 111, 531–538 (2014).
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H. & Francis, C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111, 4902–4907 (2008).
Benlice, C. et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis. Colon Rectum 61, 1170–1179 (2018).
McCurdy, J. D. et al. A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 49, 1493–1501 (2019).
Grainge, M. J., West, J. & Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657–663 (2010).
Bollen, L. et al. Thromboembolism as an important complication of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 28, 1–7 (2016).
Hansen, A. T., Erichsen, R., Horváth-Puhó, E. & Sørensen, H. T. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. J. Thromb. Haemost. 15, 702–708 (2017).
Kim, T. J. et al. Risk of venous thromboembolism according to disease activity, hospitalisation, or surgery in inflammatory bowel disease: a nationwide cohort study [abstract P196]. J. Crohns Colitis 13 (Suppl. 1), S189–S190 (2019).
Kim, Y. H. et al. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period. Medicine 98, e17309 (2019).
Ananthakrishnan, A. N. et al. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 12, 1905–1910 (2014).
Harbord, M. et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J. Crohns Colitis 10, 239–254 (2016).
Kahn, S. R. et al. Prevention of VTE in nonsurgical patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e195S–e226S (2012).
Fleming, F. et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. Dis. Colon Rectum 61, 14–20 (2018).
Laporte, S. et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J. Thromb. Haemost. 9, 464–472 (2011).
Goldhaber, S. Z. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365, 2167–2177 (2011).
Cohen, A. T. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N. Engl. J. Med. 368, 513–523 (2013).
Cohen, A. T. et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N. Engl. J. Med. 375, 534–544 (2016).
Felder, S. et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst. Rev. 3, CD004318 (2019).
Forster, R. & Stewart, M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database Syst. Rev. 3, CD004179 (2016).
Sweetland, S. et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 339, b4583 (2009).
Vedovati, M. C. et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann. Surg. 259, 665–669 (2014).
Faye, A. S. et al. Acute venous thromboembolism risk highest within 60 days after discharge from the hospital in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 18, 1133–1141.e3 (2020).
Chu, T. P. C., Grainge, M. J. & Card, T. R. The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity. Aliment. Pharmacol. Ther. 48, 1099–1108 (2018).
Trepanier, M. et al. Cost-effectiveness of extended thromboprophylaxis in patients undergoing colorectal surgery from a Canadian Health Care System perspective. Dis. Colon Rectum 62, 1381–1389 (2019).
Leeds, I. L., Dibrito, S. R., Canner, J. K., Haut, E. R. & Safar, B. Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn’s disease. Dis. Colon Rectum 62, 1371–1380 (2019).
Papay, P. et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J. Crohns Colitis 7, 723–729 (2013).
Nguyen, G. C. & Sharma, S. Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. Inflamm. Bowel Dis. 19, 2182–2189 (2013).
Novacek, G. et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 139, 779–787 (2010).
Faye, A. S. et al. Minor hematochezia decreases use of venous thromboembolism prophylaxis in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 26, 1394–1400 (2020).
Shen, J., Ran, Z. H., Tong, J. L. & Xiao, S. D. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment. Pharmacol. Ther. 26, 653–663 (2007).
Ra, G., Thanabalan, R., Ratneswaran, S. & Nguyen, G. C. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J. Crohns Colitis 7, e479–e485 (2013).
Kaddourah, O. et al. Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups. Ann. Gastroenterol. 32, 578–583 (2020).
Rosenberg, D. J. et al. External validation of the IMPROVE bleeding risk assessment model in medical patients. Thromb. Haemost. 116, 530–536 (2016).
Hostler, D. C. et al. Validation of the international medical prevention registry on venous thromboembolism bleeding risk score. Chest 149, 372–379 (2016).
Decousus, H. et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139, 69–79 (2011).
Willerson, J. T. & Ridker, P. M. Inflammation as a cardiovascular risk factor. Circulation 109, II2–II10 (2004).
Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937–952 (2004).
Aggarwal, A., Atreja, A., Kapadia, S., Lopez, R. & Achkar, J.-P. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm. Bowel Dis. 20, 1593–1601 (2014).
Aarestrup, J., Jess, T., Kobylecki, C. J., Nordestgaard, B. G. & Allin, K. H. Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals. J. Crohns Colitis 13, 319–323 (2019).
Kristensen, S. L. et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS ONE 8, e56944 (2013).
Kirchgesner, J. et al. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut 67, 1261–1268 (2018).
Le Gall, G. et al. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. PLoS ONE 13, e0201991 (2018).
Card, T. R., Zittan, E., Nguyen, G. C. & Grainge, M. J. Disease activity in inflammatory bowel disease is associated with arterial vascular disease. Inflamm. Bowel Dis. 27, 629–638 (2021).
Sun, H. H. & Tian, F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur. J. Prev. Cardiol. 25, 1623–1631 (2018).
Singh, S., Singh, H., Loftus, E. V. & Pardi, D. S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 12, 382–393.e1 (2014).
Singh, S., Kullo, I. J., Pardi, D. S. & Loftus, E. V. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat. Rev. Gastroenterol. Hepatol. 12, 26–35 (2015).
Feng, W. et al. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J. Am. Heart Assoc. 6, e005892 (2017).
Lin, T. Y., Chen, Y. G., Lin, C. L., Huang, W. S. & Kao, C. H. Inflammatory bowel disease increases the risk of peripheral arterial disease: a nationwide cohort study. Medicine 94, e2381 (2015).
Danese, S. et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130, 2060–2073 (2006).
Sagan, A. et al. Local inflammation is associated with aortic thrombus formation in abdominal aortic aneurysms. Relationship to clinical risk factors. Thromb. Haemost. 108, 812–823 (2012).
Tsai, M. S. et al. Long-term risk of mesenteric ischemia in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. Am. J. Surg. 210, 80–86 (2015).
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596–e646 (2019).
Papa, A. et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 96, 2677–2682 (2001).
Oldenburg, B., Van Tuyl, B. A. C., van der Griend, R., Fijnheer, R. & van Berge Henegouwen, G. P. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig. Dis. Sci. 50, 235–240 (2005).
Tsigkas, G. et al. Inflammatory bowel disease: a potential risk factor for coronary artery disease. Angiology 68, 845–849 (2017).
Wu, P., Jia, F., Zhang, B. & Zhang, P. Risk of cardiovascular disease in inflammatory bowel disease. Exp. Ther. Med. 13, 395–400 (2017).
D’Agostino, R. B. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743–753 (2008).
Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 37, 2315–2381 (2016).
Goff, D. C. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49–S73 (2014).
Mahmoodi, B. K. et al. Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta-analysis of prospective studies. Circulation 135, 7–16 (2017).
Galloway, J. et al. Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. RMD Open 6, e001392 (2020).
Piovani, D. et al. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157, 647–659.e4 (2019).
Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255–323 (2020).
ASCEND Study Collaborative Group. et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539 (2018).
Gaziano, J. M. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392, 1036–1046 (2018).
Mahmoud, A. N., Gad, M. M., Elgendy, A. Y., Elgendy, I. Y. & Bavry, A. A. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur. Heart J. 40, 607–617 (2019).
McNeil, J. J. et al. Effect of aspirin on all-cause mortality in the healthy elderly. N. Engl. J. Med. 379, 1519–1528 (2018).
Li, L., Geraghty, O. C., Mehta, Z. & Rothwell, P. M., Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390, 490–499 (2017).
Patel, P. et al. Daily aspirin use does not impact clinical outcomes in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 27, 236–241 (2021).
Carty, M. & Rampton. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14, 1169–1179 (2000).
Winther, K., Bondesen, S., Hansen, S. H. & Hvidberg, E. F. Lack of effect of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro. Eur. J. Clin. Pharmacol. 33, 419–422 (1987).
Sehgal, P., Colombel, J.-F., Aboubakr, A. & Narula, N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment. Pharmacol. Ther. 47, 1597–1609 (2018).
Małyszko, J., Małyszko, J. S., Takada, A. & Myśliwiec, M. Effects of immunosuppressive drugs on platelet aggregation in vitro. Ann. Transplant. 7, 55–68 (2002).
Irving, P. M. et al. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm. Bowel Dis. 10, 361–372 (2004).
Macaluso, F. S. et al. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scand. J. Gastroenterol. 52, 981–987 (2017).
den Heijer, M., Rosendaal, F. R., Blom, H. J., Gerrits, W. B. & Bos, G. M. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb. Haemost. 80, 874–877 (1998).
van Ede, A. E. et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 41, 658–665 (2002).
Oussalah, A., Guéant, J.-L. & Peyrin-Biroulet, L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 34, 1173–1184 (2011).
Vasudevan, A. et al. Thiopurines vs methotrexate: comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 52, 1174–1184 (2020).
Rungoe, C. et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 62, 689–694 (2013).
Higgins, P. D. R., Skup, M., Mulani, P. M., Lin, J. & Chao, J. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 13, 316–321 (2015).
Waljee, A. K. et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. PLoS ONE 11, e0158017 (2016).
Sarlos, P. et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis. J. Crohns Colitis 12, 489–498 (2018).
Wei, L., MacDonald, T. M. & Walker, B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 141, 764–770 (2004).
Roubille, C. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 74, 480–489 (2015).
Andersohn, F., Waring, M. & Garbe, E. Risk of ischemic stroke in patients with Crohn’s disease: a population-based nested case-control study. Inflamm. Bowel Dis. 16, 1387–1392 (2010).
Bollen, L. et al. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm. Bowel Dis. 21, 570–578 (2015).
Detrez, I. et al. Successful infliximab treatment is associated with reversal of clotting abnormalities in inflammatory bowel disease patients. J. Clin. Gastroenterol. 54, 819–825 (2020).
DeFonseka, A. M., Tuskey, A., Conaway, M. R. & Behm, B. W. Antitumor necrosis factor-α therapy is associated with reduced risk of thromboembolic events in hospitalized patients with inflammatory bowel disease. J. Clin. Gastroenterol. 50, 578–583 (2016).
Desai, R. J. et al. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study. CMAJ 189, E1438–E1447 (2017).
Lichtenstein, G. R. et al. Infliximab for Crohn’s disease: more than 13 years of real-world experience. Inflamm. Bowel Dis. 24, 490–501 (2018).
Cross, R. K. et al. The incidence of cardiovascular events in patients with Crohn’s disease treated with vedolizumab and anti-TNF therapies [abstract Su1870]. Gastroenterology 152 (Suppl. 1), 577–578 (2017).
Colombel, J.-F. et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66, 839–851 (2017).
Narula, N. et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am. J. Gastroenterol. 113, 1345 (2018).
Plevris, N. et al. Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish Vedolizumab Cohort. J. Crohns Colitis 13, 1111–1120 (2019).
Papp, K. et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J. Drugs Dermatol. 14, 706–714 (2015).
Lewis, J. D. et al. Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-α-directed therapy for inflammatory bowel disease. Am. J. Gastroenterol. 113, 405–417 (2018).
Kirchgesner, J., Nyboe Andersen, N., Carrat, F., Jess, T. & Beaugerie, L. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: Nationwide French cohort study. Gut 69, 852–858 (2020).
Fumery, M. et al. Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis [abstract 303]. Gastroenterology 152 (Suppl. 1), S77 (2017).
Cohen, R. D., Bhayat, F., Blake, A. & Travis, S. The safety profile of vedolizumab in ulcerative colitis and Crohn’s Disease: 4 years of global post-marketing data. J. Crohns Colitis 14, 192–204 (2020).
D’Amico, F., Parigi, T. L., Bonovas, S., Peyrin-Biroulet, L. & Danese, S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin. Drug Saf. 19, 807–816 (2020).
Rungapiromnan, W., Yiu, Z. Z. N., Warren, R. B., Griffiths, C. E. M. & Ashcroft, D. M. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br. J. Dermatol. 176, 890–901 (2017).
Poizeau, F. et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 156, 1208–1215 (2020).
European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. EMA https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz (2020).
Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). FDA https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (2021).
Desai, R. J., Pawar, A., Weinblatt, M. E. & Kim, S. C. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study. Arthritis Rheumatol. 71, 892–900 (2019).
Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S. & Peyrin-Biroulet, L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158, 1554–1573.e12 (2020).
Sandborn, W. J. et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment. Pharmacol. Ther. 50, 1068–1076 (2019).
Bernstein, C. N., Blanchard, J. F., Houston, D. S. & Wajda, A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85, 430–434 (2001).
Deepak, P. et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 10.1016/j.cgh.2020.06.050 (2020). DOI: 10.1016/j.cgh.2020.06.050
McInnes, I. B. et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann. Rheum. Dis. 73, 124–131 (2014).
Sands, B. E. et al. Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 18, 123–132.e3 (2020).
Pfizer. FDA Advisory Committee Meeting sNDA 203214 Briefing Document. FDA https://www.fda.gov/media/111383/download (2018).
Sandborn, W. J. et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin. Gastroenterol. Hepatol. 17, 1541–1550 (2019).
Xie, W. et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 78, 1048–1054 (2019).